Form 4: Arcutis Biotherapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Todd Franklin Watanabe, CEO of Arcutis Biotherapeutics, sold 14,487 shares of common stock on August 2, 2024, to satisfy tax withholding obligations related to vesting Restricted Stock Units.
Summary
- On August 2, 2024, Todd Franklin Watanabe, the President and CEO of Arcutis Biotherapeutics, sold 14,487 shares of the company's common stock.
- The sale was executed under a Rule 10b5-1 trading plan to cover tax withholding obligations associated with the vesting of Restricted Stock Units.
- The shares were sold at a weighted average price of $9.0183, with individual transactions ranging from $8.74 to $9.26.
- Following the transaction, Watanabe directly owns 846,263 shares of Arcutis Biotherapeutics.
- Watanabe also has indirect ownership through various trusts and an LLC, totaling 230,140 shares.
- He disclaims beneficial ownership of these indirectly held shares except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The sale is related to tax obligations, which is a common practice. Therefore, the sentiment is neutral.
Industry Context
Sales of shares by company executives are a normal part of corporate governance. Often these sales are pre-planned to avoid any accusations of insider trading.
Key Dates
| Date | Description |
|---|---|
| 08/02/2024 | Date of stock sale transaction |
| 08/05/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.